Imprimis Pharmaceuticals Gets $16M In Debt Funding

San Diego-based Imprimis Pharmaceuticals, the publicly held, ophthalmology pharmaceuticals developer, said it has received $16M in a senior secured non-dilutive term loan agreement from SWK Funding LLC. The company said the new funding will go to retire an existing, $13M term loan it has with Life Sciences Alternative Funding LLC, and also will go to provide additional working capital to the company. Imprimis Pharmaceuticals said the term loan has a five year term, with 12 percent interest-only payments for the first eighteen months.